Relistor methylnaltrexone: Phase II started

Ono began a double-blind, placebo-controlled, Japanese Phase II trial to evaluate ONO-3849 in patients. Subcutaneous methylnaltrexone is approved in over 40 countries as Relistor to treat OIC in patie...